Analysts’ Viewpoint
Rise in incidence of heart diseases, increase in awareness about the health risks associated with high cholesterol levels, and availability of effective drugs are significant factors driving the global market for lipid-lowering drugs. Increase in healthcare spending, growth in geriatric population, and rise in awareness about the benefits of early detection and treatment of cardiovascular diseases are expected to fuel market progress in the near future.
Advancements in drug development are also expected to drive the global market in the next few years. Companies in the global market are investing in R&D to introduce effective and safe medications for patients with high cholesterol levels. Moreover, surge in demand for lipid-lowering drugs in emerging economies and growth in number of clinical trials focused on cardiac treatments are creating lucrative lipid-lowering drugs market opportunities for market participants.
Lipid-lowering agents are medications that are used to lower the levels of cholesterol and other lipids (fats) in the blood. These drugs are typically prescribed to people with high levels of cholesterol or people suffering from cardiovascular diseases, such as diabetes, high blood pressure, or heart disease. There are several classes of lipid-lowering medications such as statins, ezetimibe, PCSK9 inhibitors, fibrates, and niacin.
Statins are the drugs that inhibit the enzyme HMG-CoA reductase, which is involved in the production of cholesterol in the liver. Statins are highly effective at lowering LDL (‘bad’) cholesterol levels and reducing the risk of cardiovascular events such as heart attack and stroke. Ezetimibe works by blocking the absorption of cholesterol in the intestines, thereby reducing the amount of cholesterol that enters the bloodstream.
PCSK9 inhibitors work by blocking the PCSK9 protein, which plays a role in the breakdown of LDL cholesterol in the liver. Fibrates can lower triglyceride levels and raise HDL (‘good’) cholesterol levels. They are often used in combination with statins. Niacin, or Vitamin B3, can also raise HDL cholesterol levels and lower LDL cholesterol levels. It is often used in combination with other lipid-lowering drugs.
Cardiovascular diseases (CVDs) are a leading cause of death globally and are associated with high levels of cholesterol in the blood. Lipid-regulating drugs are a class of medications that are used to lower cholesterol levels in the blood and reduce the risk of CVDs.
According to the World Health Organization (WHO), CVD is the leading cause of death globally. As per estimation, around 17.9 million people died from CVD in 2019, which represents around 32% of the deaths globally. Moreover, 85% of deaths occurred due to strokes and heart attacks. Thus, high prevalence of CVDs is anticipated to augment the lipid-lowering drugs market value in the near future.
Lipid-lowering drugs, also known as cholesterol-lowering drugs, are used to reduce cholesterol levels in the blood and are prescribed to people with high cholesterol levels. Several advancements in drug development have been witnessed in the global market for lipid-lowering drugs in the last few years.
PCSK9 inhibitors are a new class of drugs that help lower LDL cholesterol levels by blocking the PCSK9 protein, which reduces the number of LDL receptors in the liver. In 2015, the FDA approved two PCSK9 inhibitors: evolocumab and alirocumab.
Moreover, there has been a trend toward developing combination therapies that use two or more lipid-lowering drugs with different mechanisms of action to achieve greater cholesterol-lowering effects. Examples of combination therapies include statins plus ezetimibe and statins plus PCSK9 inhibitors.
Gene therapy is also a new approach to treating high cholesterol levels. It involves introducing a new gene into the body to replace a defective or missing gene that is responsible for producing a protein that helps regulate cholesterol levels.
Several drugs are under development that use novel mechanisms of action to lower cholesterol levels. For instance, bempedoic acid inhibits an enzyme called ATP citrate lyase, which is involved in the production of cholesterol in the liver.
In terms of drug class, the global market has been divided into statins & combination, PCSK9 inhibitors, bile acid sequestrants, fibrates, cholesterol absorption inhibitors, and others. According to the latest lipid-lowering drugs market forecast report, the statins & combination drug class segment is projected to dominate the global market during the forecast period. This segment held major share of the global market in 2022.
Statins are a type of medication that is used to decrease cholesterol levels in the blood. They function by blocking the enzyme HMG-CoA reductase, which is involved in cholesterol synthesis in the liver. Statins are among the most commonly prescribed medications, and they have been found to reduce the incidence of cardiovascular events such as heart attacks and strokes.
Based on indication, the global market has been segregated into hypercholesterolemia, coronary artery disease, and high triglycerides. The hypercholesterolemia indication segment accounted for major share of the global market in 2022. It is anticipated to maintain its dominance during the forecast period.
Hypercholesterolemia is a medical condition characterized by high levels of cholesterol in the blood. Hypercholesterolemia can be caused by several factors, which include genetics, diet, and lifestyle. People with a family history of high cholesterol are more likely to develop the condition.
A diet high in saturated and trans fats can also contribute to high cholesterol levels. Additionally, lack of physical activity, smoking, and obesity can increase the risk of developing hypercholesterolemia. Demand for lipid-lowering drugs is rising due to increase in incidence of hypercholesterolemia.
In terms of distribution channel, the global market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. According to the latest lipid-lowering drugs market trends, the retail pharmacies distribution channel segment is likely to dominate the global market during the forecast period. This segment held major share of the global market in 2022.
Retail pharmacies offer several benefits to consumers including convenience and ease of access. This has led to increase in consumer preference for retail pharmacies.
According to the lipid-lowering drugs market analysis, North America dominated the global market in 2022. It is likely to maintain its dominance during the forecast period. Lipid-lowering drugs market demand is increasing in the region due to rise in prevalence of cardiovascular diseases.
According to the Centers for Disease Control and Prevention, almost 94 million people in the U. S. aged 20 years and above have high cholesterol levels, i.e. greater than 200 mg/dL. This drives demand for lipid-lowering drugs in the U.S., further fueling lipid-lowering drugs market development in North America.
The lipid-lowering drugs market size in Asia Pacific is likely to increase during the forecast period. The region has a high number of cardiovascular patients. This factor is fueling lipid-lowering drugs industry growth in the region. According to the American College of Cardiology Foundation, CVD was the biggest cause of mortality in Asia Pacific in 2019, accounting for 10.8 million deaths, or nearly 35% of all deaths in Asia Pacific.
The global industry is fragmented, with the presence of a large number of local as well as international players that control majority of the lipid-lowering drugs market share. According to the latest lipid-lowering drugs market research report, leading players are implementing innovative strategies strengthen their market share. Some of the major strategies include expansion of product portfolio and mergers & acquisitions.
Leading players operating in the global market are Sanofi, Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., AbbVie, Inc., Viatris (Mylan N.V.), AstraZeneca PLC, and Dr. Reddy’s Laboratories Ltd.
Key players have been profiled in the lipid-lowering drugs market report based on parameters such as company overview, product portfolio, business strategies, recent developments, financial overview, and business segments.
|
Attribute |
Detail |
|
Market Size Value in 2022 |
US$ 31.4 Bn |
|
Market Forecast Value in 2031 |
US$ 42.5 Bn |
|
Growth Rate (CAGR) |
3.4% |
|
Forecast Period |
2023–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global market was valued at US$ 31.4 Bn in 2022
It is projected to reach more than US$ 42.5 Bn by 2031
The CAGR is anticipated to be 3.4% from 2023 to 2031
Increase in prevalence of cardiovascular diseases and rise in geriatric population
North America is expected to account for major share during the forecast period
Sanofi, Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., AbbVie, Inc., Viatris (Mylan N.V.), AstraZeneca PLC, and Dr. Reddy’s Laboratories Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Lipid-lowering Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Lipid-lowering Drugs Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Drug Pipeline Analysis
5.2. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
5.3. Regulatory Scenario by Region/globally
5.4. Patent Analysis
6. Global Lipid-lowering Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017-2031
6.3.1. Statins & Combination
6.3.2. PCSK9 Inhibitors
6.3.3. Bile Acid Sequestrants
6.3.4. Fibrates
6.3.5. Cholesterol Absorption Inhibitors
6.3.6. Others
6.4. Market Attractiveness, by Drug Class
7. Global Lipid-lowering Drugs Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Indication, 2017-2031
7.3.1. Hypercholesterolemia
7.3.2. Coronary Artery Disease
7.3.3. High Triglycerides
7.4. Market Attractiveness, by Indication
8. Global Lipid-lowering Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017-2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness, by Distribution Channel
9. Global Lipid-lowering Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Country/Region
10. North America Lipid-lowering Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017-2031
10.2.1. Statins & Combination
10.2.2. PCSK9 Inhibitors
10.2.3. Bile Acid Sequestrants
10.2.4. Fibrates
10.2.5. Cholesterol Absorption Inhibitors
10.2.6. Others
10.3. Market Value Forecast, by Indication, 2017-2031
10.3.1. Hypercholesterolemia
10.3.2. Coronary Artery Disease
10.3.3. High Triglycerides
10.4. Market Value Forecast, by Distribution Channel, 2017-2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Indication
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Lipid-lowering Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017-2031
11.2.1. Statins & Combination
11.2.2. PCSK9 Inhibitors
11.2.3. Bile Acid Sequestrants
11.2.4. Fibrates
11.2.5. Cholesterol Absorption Inhibitors
11.2.6. Others
11.3. Market Value Forecast, by Indication, 2017-2031
11.3.1. Hypercholesterolemia
11.3.2. Coronary Artery Disease
11.3.3. High Triglycerides
11.4. Market Value Forecast, by Distribution Channel, 2017-2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Indication
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Lipid-lowering Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017-2031
12.2.1. Statins & Combination
12.2.2. PCSK9 Inhibitors
12.2.3. Bile Acid Sequestrants
12.2.4. Fibrates
12.2.5. Cholesterol Absorption Inhibitors
12.2.6. Others
12.3. Market Value Forecast, by Indication, 2017-2031
12.3.1. Hypercholesterolemia
12.3.2. Coronary Artery Disease
12.3.3. High Triglycerides
12.4. Market Value Forecast, by Distribution Channel, 2017-2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Indication
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Lipid-lowering Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017-2031
13.2.1. Statins & Combination
13.2.2. PCSK9 Inhibitors
13.2.3. Bile Acid Sequestrants
13.2.4. Fibrates
13.2.5. Cholesterol Absorption Inhibitors
13.2.6. Others
13.3. Market Value Forecast, by Indication, 2017-2031
13.3.1. Hypercholesterolemia
13.3.2. Coronary Artery Disease
13.3.3. High Triglycerides
13.4. Market Value Forecast, by Distribution Channel, 2017-2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast By Country/Sub-region, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Indication
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Lipid-lowering Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017-2031
14.2.1. Statins & Combination
14.2.2. PCSK9 Inhibitors
14.2.3. Bile Acid Sequestrants
14.2.4. Fibrates
14.2.5. Cholesterol Absorption Inhibitors
14.2.6. Others
14.3. Market Value Forecast, by Indication, 2017-2031
14.3.1. Hypercholesterolemia
14.3.2. Coronary Artery Disease
14.3.3. High Triglycerides
14.4. Market Value Forecast, by Distribution Channel, 2017-2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Indication
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share/Ranking Analysis By Company (2022)
15.3. Company Profiles
15.3.1. Sanofi
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Strategic Overview
15.3.2. Pfizer, Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Strategic Overview
15.3.3. GlaxoSmithKline plc
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Strategic Overview
15.3.4. Novartis AG
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Strategic Overview
15.3.5. Merck & Co., Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Strategic Overview
15.3.6. Amgen Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Strategic Overview
15.3.7. Takeda Pharmaceutical Company Limited
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Strategic Overview
15.3.8. Sun Pharmaceutical Industries Ltd.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Strategic Overview
15.3.9. AbbVie, Inc.
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Strategic Overview
15.3.10. Viatris (Mylan N.V.)
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Strategic Overview
15.3.11. AstraZeneca PLC
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Strategic Overview
15.3.12. Dr. Reddy’s Laboratories Ltd.
15.3.12.1. Company Overview
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Strategic Overview
List of Tables
Table 01: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 02: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by 2017‒2031, by Indication
Table 03: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 07: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 08: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 10: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 11: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 12: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 15: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 16: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 19: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 20: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 23: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 24: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Lipid-lowering Drugs Market Value Share, by Drug Class, 2021
Figure 03: Global Lipid-lowering Drugs Market Value Share, by Indication, 2021
Figure 04: Global Lipid-lowering Drugs Market Value Share, by Distribution Channel, 2021
Figure 05: Global Lipid-lowering Drugs Market Value Share Analysis, by Drug Class, 2021 and 2031
Figure 06: Global Lipid-lowering Drugs Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 09: Global Lipid-lowering Drugs Market Value Share Analysis, by Indication, 2021 and 2031
Figure 10: Global Lipid-lowering Drugs Market Attractiveness Analysis, by Indication, 2022–2031
Figure 11: Global Lipid-lowering Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 12: Global Lipid-lowering Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 13: Global Lipid-lowering Drugs Market Value Share Analysis, by Region, 2021 and 2031
Figure 14: Global Lipid-lowering Drugs Market Attractiveness Analysis, by Region, 2022–2031
Figure 15: North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 16: North America Lipid-lowering Drugs Market Value Share Analysis, by Country, 2021 and 2031
Figure 17: North America Lipid-lowering Drugs Market Attractiveness Analysis, by Country, 2022–2031
Figure 18: North America Lipid-lowering Drugs Market Value Share Analysis, by Drug Class, 2021 and 2031
Figure 19: North America Lipid-lowering Drugs Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 20: North America Lipid-lowering Drugs Market Value Share Analysis, by Indication, 2021 and 2031
Figure 21: North America Lipid-lowering Drugs Market Attractiveness Analysis, by Indication, 2022–2031
Figure 22: North America Lipid-lowering Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 23: North America Lipid-lowering Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 24: Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 25: Europe Lipid-lowering Drugs Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 26: Europe Lipid-lowering Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 27: Europe Lipid-lowering Drugs Market Value Share Analysis, by Drug Class, 2021 and 2031
Figure 28: Europe Lipid-lowering Drugs Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 29: Europe Lipid-lowering Drugs Market Value Share Analysis, by Indication, 2021 and 2031
Figure 30: Europe Lipid-lowering Drugs Market Attractiveness Analysis, by Indication, 2022–2031
Figure 31: Europe Lipid-lowering Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 32: Europe Lipid-lowering Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 33: Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 34: Asia Pacific Lipid-lowering Drugs Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 35: Asia Pacific Lipid-lowering Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 36: Asia Pacific Lipid-lowering Drugs Market Value Share Analysis, by Drug Class, 2021 and 2031
Figure 37: Asia Pacific Lipid-lowering Drugs Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 38: Asia Pacific Lipid-lowering Drugs Market Value Share Analysis, by Indication, 2021 and 2031
Figure 39: Asia Pacific Lipid-lowering Drugs Market Attractiveness Analysis, by Indication, 2022–2031
Figure 40: Asia Pacific Lipid-lowering Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 41: Asia Pacific Lipid-lowering Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 42: Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 43: Latin America Lipid-lowering Drugs Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031
Figure 44: Latin America Lipid-lowering Drugs Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031
Figure 45: Latin America Lipid-lowering Drugs Market Value Share Analysis, by Drug Class, 2021 and 2031
Figure 46: Latin America Lipid-lowering Drugs Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 47: Latin America Lipid-lowering Drugs Market Value Share Analysis, by Indication, 2021 and 2031
Figure 48: Latin America Lipid-lowering Drugs Market Attractiveness Analysis, by Indication, 2022–2031
Figure 49: Latin America Lipid-lowering Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 50: Latin America Lipid-lowering Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 51: Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 52: Middle East & Africa Lipid-lowering Drugs Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031
Figure 53: Middle East & Africa Lipid-lowering Drugs Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031
Figure 54: Middle East & Africa Lipid-lowering Drugs Market Value Share Analysis, by Drug Class, 2021 and 2031
Figure 55: Middle East & Africa Lipid-lowering Drugs Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 56: Middle East & Africa Lipid-lowering Drugs Market Value Share Analysis, by Indication, 2021 and 2031
Figure 57: Middle East & Africa Lipid-lowering Drugs Market Attractiveness Analysis, by Indication, 2022–2031
Figure 58: Middle East & Africa Lipid-lowering Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 59: Middle East & Africa Lipid-lowering Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 60: Company Share Analysis, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Lipid-lowering Drugs Market
*86 figures and 60 tables includes